RxDoctor Payments Data

Michael Patti, MD

Family Medicine · Waynesboro, PANPI 1700884475

Payments from drug & device makers

$2,465in general payments, 2019–2025

Across 135 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$608
  • Novo Nordisk$389
  • AstraZeneca$349
  • Bone Support Inc.$185
  • Bayer$140
  • Boehringer Ingelheim$135
  • plus $659 from 16 others

What the payments were for

  • Food & beverage$2,465100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,465 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$14,667
Medicare patients
93
Services billed
132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide51$80,528
FarxigaDapagliflozin Propanediol28$33,887
JardianceEmpagliflozin21$29,156
JanuviaSitagliptin Phosphate26$25,675
SymbicortBudesonide/Formoterol Fumarate18$4,631
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$4,151
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,424
Gabapentin48$1,336
Rosuvastatin Calcium61$1,265
Atorvastatin Calcium134$1,253
Omeprazole77$1,205
Amlodipine Besylate115$819
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide23$755
Lisinopril94$707
Losartan Potassium58$691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$608$80,52851 claims
AstraZenecaFarxiga, Symbicort$349$38,51846 claims
Boehringer IngelheimJardiance$135$29,15621 claims
MerckJanuvia$83$25,67526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Waynesboro

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →